Rotavirus vaccines
AssigneeCure Vac SE
InventorsSusanne Rauch, Benjamin Petsch
Life of this patent
Estimating the term…
Abstract
The present invention provides mRNA sequences comprising at least one coding region, encoding for at least one epitope of a protein, or of a fragment, variant or derivative thereof, of a virus of the genus rotavirus. Particularly preferred is the protein respectively the protein cleavage product VP8* of rotavirus. The mRNA sequence may be used as a vaccine or generally as a pharmaceutical composition for prophylaxis or treatment of rotavirus infections.
Claims20
An immune stimulating composition comprising purified RNA molecules encoding rotavirus VP4 antigens from at least two serotypes of rotavirus, wherein each purified RNA molecule encodes a polypeptide comprising at least 100 amino acids of a VP8* cleavage product of the rotavirus VP4 antigen, said purified RNA molecules comprising:
- a m7GpppN 5′ Cap, at least one heterologous untranslated region (UTR) and Poly-A sequence, wherein the purified RNA molecules are formulated in a pharmaceutically acceptable carrier comprising lipid nanoparticles (LNPs).
Dependencies are inferred from the claim text.